McClellan Michael James 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2018
Insider Transaction Report
Form 4
McClellan Michael James
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2018-03-03+1,049→ 11,377.272 total - Tax Payment
Ordinary Shares
2018-03-05$19.38/sh−455$8,818→ 10,922.272 total - Exercise/Conversion
Restricted Share Units
2018-03-03−1,049→ 3,148 total→ Ordinary Shares (1,049 underlying)
Footnotes (3)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Restricted share units were granted on March 3, 2017, with 1,049 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,050 vesting on Mach 3, 2021.